Edgewise Therapeutics, Inc., has initiated the participation induction for GRAND CANYON, an international principal examination of EDG-5506 designed for Becker patients.

This article summarized the latest R&D progress of Crisaborole, the Mechanism of Action for Crisaborole, and the drug target R&D trends for Crisaborole.

Arcturus Therapeutics and the Cystic Fibrosis Foundation continue partnership to further the development of ARCT-032, an experimental mRNA therapy for Cystic Fibrosis.

ROCK, also known as Rho-associated coiled-coil kinases, is a class of serine/threonine protein kinases that play an important role in various common cellular functions such as cell proliferation, cell apoptosis, and gene expression.

This article summarized the latest R&D progress of Clofazimine, the Mechanism of Action for Clofazimine, and the drug target R&D trends for Clofazimine.

Inozyme Pharma reports encouraging preliminary results from ongoing INZ-701 phase 1/2 studies in adults with ENPP1 and ABCC6 (PXE) deficiencies.

This article summarized the latest R&D progress of Clevidipine, the Mechanism of Action for Clevidipine, and the drug target R&D trends for Clevidipine.

Omega Therapeutics, Inc. reported positive early findings from the first two doses of its Phase 1/2 MYCHELANGELO™ I study on OTX-2002. The study focuses on hepatocellular carcinoma patients and others with solid tumors linked to the c-MYC gene.

This article summarized the latest R&D progress of Cinnarizine, the Mechanism of Action for Cinnarizine, and the drug target R&D trends for Cinnarizine.

SOS1, is a protein that plays a crucial role in signal transduction pathways within the human body.

Immunovant, Inc. recently revealed preliminary results of a Phase 1 clinical trial for IMVT-1402.

This article summarized the latest R&D progress of Carfilzomib, the Mechanism of Action for Carfilzomib, and the drug target R&D trends for Carfilzomib.